US FDA And Congressional Oversight: Will Democrats Be Tougher Than The GOP?
Executive Summary
Most US agencies can expect relatively friendly oversight from a Democratic Congress. The US FDA might be one exception, as a recent House hearing on foreign inspections shows.
You may also be interested in...
US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.
Inspection Questions Delay CBER’s Embrace Of Real-Time Oncology Review
The oncology branch of the US FDA’s biologics center does not believe RTOR would speed application reviews.
COVID Vaccine ‘Miracle’ May Set Unrealistic Expectations For US Supply Chains
The story of the US coronavirus vaccine production ramp-up is putting the drug industry in an extraordinarily favorable public relations position. One downside, however, may be complicating the industry’s message about the limits of ‘Buy American’ efforts on pharmaceutical supply chains overall.